Market Place
Sourcing Support
Can-Fite Starts Phase 3 Psoriasis Study of Piclidenoson with FDA
24 Mar 2025 //
GLOBENEWSWIRE
Can-Fite, Vetbiolix Accelerate Piclidenoson Develop in $3.8B Market
20 Mar 2025 //
GLOBENEWSWIRE
Patient Improvement Reported With Namodenoson In Liver Cirrhosis
01 Jul 2024 //
GLOBENEWSWIRE
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson
18 Aug 2023 //
BUSINESSWIRE
Can-Fite Receives USFDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
29 Jun 2023 //
BUSINESSWIRE
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Companies
16 Mar 2023 //
BUSINESSWIRE
Can-Fite Submits Market Registration Plan to EMA for Piclidenoson
10 Jan 2023 //
BUSINESSWIRE
Can-Fite: New PIII Psoriasis Data Showing Superior Safety & Improved Efficacy
12 Sep 2022 //
BUSINESSWIRE
Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis
17 Aug 2022 //
BUSINESSWIRE
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in Psoriasis
11 Jul 2022 //
BUSINESSWIRE
Can-Fite to Present at Dermatology Drug Development Summit Europe
28 Mar 2022 //
BUSINESSWIRE
Can-Fite CEO to Present Namodenoson’s Clinical Trial Data
26 Oct 2021 //
BUSINESSWIRE
Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance
15 Jul 2020 //
BUSINESSWIRE
Applied Biology and Kintor to Collaborate on the use of Proxalutamide
14 Jul 2020 //
BUSINESSWIRE
Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance
14 Jul 2020 //
BUSINESSWIRE
Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Ph II
09 Jun 2020 //
BUSINESSWIRE
Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson
15 May 2020 //
BUSINESSWIRE
Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Enrollment
13 Apr 2020 //
BUSINESSWIRE
Can-Fite Updates on Milestone for its Ph III Rheumatoid Arthritis Piclidenoson
05 Mar 2020 //
BIOSPACE
Can-Fite is Filing Drug Safety Update-Ph II & Ph III Namodenoson & Piclidenoson
03 Mar 2020 //
BUSINESSWIRE
Can-Fite Completes 50% Patient Enrollment in PhIII Rheumatoid Arthritis Study
03 Feb 2020 //
BUSINESSINSIDER
Drugs with MOA Utilized by Namodenoson Recommended to Combat Liver Cancer
02 Jul 2018 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.